Hematology/Oncology

Top Story

FDA advisory committee split on opinion of adjuvant Sutent for renal cell carcinoma

September 19, 2017

The FDA’s Oncologic Drug Advisory Committee today voted 6-6 on whether the risk-benefit profile of sunitinib malate is acceptable for the adjuvant treatment of patients with a high-risk for recurrent renal cell carcinoma following nephrectomy.

The committee considered data from the S-TRAC trial, which randomly assigned patients at high risk for recurrent renal cell carcinoma following nephrectomy to 1 year of sunitinib (Sutent, Pfizer Oncology; n = 309) or placebo (n = 306). Patients assigned sunitinib received 50-mg doses for 4 weeks following by 2 weeks off, and the dose could be reduced to 37.5 mg.

Meeting NewsPerspective

Nivolumab plus ipilimumab outperforms sunitinib in certain kidney cancers

September 19, 2017
MADRID — The immunotherapy combination of nivolumab plus ipilimumab improved objective response rate and prolonged PFS compared with sunitinib in intermediate- and…
Meeting News

Sitravatinib plus nivolumab demonstrates early efficacy in advanced NSCLC

September 19, 2017
CHICAGO — The combination of sitravatinib and nivolumab conferred partial responses in a small cohort of patients who previously progressed on checkpoint inhibitor…
In the Journals Plus

Consolidation with arsenic trioxide effective for pediatric acute promyelocytic leukemia

September 19, 2017
Children with acute promyelocytic leukemia achieved excellent survival rates with low risk for relapse following two cycles of arsenic trioxide consolidation and reduced…
Meeting NewsVideo

VIDEO: Additional treatment with ALK inhibitor after progression shows promise in non-small cell lung cancer

September 18, 2017
CHICAGO — Ensartinib shows promise for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, Makenzi Evangelist
More Headlines »
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Video
Meeting News

VIDEO: Pembrolizumab represents ‘important option’ for metastatic urothelial cancer

June 25, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement